PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32174780-6 2020 S100A8 and S100A9 also induce the phosphorylation of AKT, ERK, p38 MAPK and JNK, and activation of NF-kappaB, which were blocked after exposure to TLR4i, LY294002, AKTi, PD98059, SB202190 or SP600125. pyrazolanthrone 191-199 nuclear factor kappa B subunit 1 Homo sapiens 99-108 28455228-6 2017 Besides, SP600125 and SB203580 also reversed the inactivation of NF-kappab and Stat3. pyrazolanthrone 9-17 nuclear factor kappa B subunit 1 Homo sapiens 65-74 30171832-6 2019 The IL-22-induced down-regulation of Cx43 expression and decrease in GJIC can be significantly blocked by the JNK inhibitor SP600125 and by the overexpression of IL-22RA2 (which specifically binds to IL-22 and inhibits its activity), but not by the NF-kappaB inhibitor BAY11-7082, in HaCaT cells. pyrazolanthrone 124-132 nuclear factor kappa B subunit 1 Homo sapiens 249-258 28432555-5 2017 Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced the TNF-alpha-induced production of inflammatory mediators, binding of NF-kappaB to DNA, and activation of the JNK and p38-MAPK in keratinocytes. pyrazolanthrone 25-33 nuclear factor kappa B subunit 1 Homo sapiens 138-147 30073566-6 2018 Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2. pyrazolanthrone 63-71 nuclear factor kappa B subunit 1 Homo sapiens 14-23 28749049-8 2018 When hPDLSCs were treated with the inhibitors of NF-kappaB and MAPK pathways (U0126, SP600125, SB203580, and BMS345541), the effects of MTA on the differentiation of hPDLSCs were suppressed. pyrazolanthrone 85-93 nuclear factor kappa B subunit 1 Homo sapiens 49-58 29042991-7 2017 Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs. pyrazolanthrone 124-132 nuclear factor kappa B subunit 1 Homo sapiens 344-353 23485395-7 2013 The p38 MAPK dependent phosphorylation of p65 NF-kappaB subunit in the nucleus was increased by SP600125 treatment. pyrazolanthrone 96-104 nuclear factor kappa B subunit 1 Homo sapiens 46-55 25996379-8 2015 In contrast, in the presence of JNK inhibitor (SP600125), p65 induced a marked increase of SOD1 promoter, suggesting that JNK pathway is up-stream of NF-kappaB signaling and controls negatively its activity. pyrazolanthrone 47-55 nuclear factor kappa B subunit 1 Homo sapiens 150-159 23712703-5 2013 Furthermore, HMGB1-induced RAGE protein expression, JNK and NF-kappaB activation were attenuated by the pretreatment with RAGE-Ab or JNK inhibitor SP600125 in Western blot analysis. pyrazolanthrone 147-155 nuclear factor kappa B subunit 1 Homo sapiens 60-69 28099584-10 2017 When treated with SP600125 and 131I, the non-transfected SW579 cell lines significantly inhibited JNK pathway, NF-kappaB pathway and the expression of BTG2. pyrazolanthrone 18-26 nuclear factor kappa B subunit 1 Homo sapiens 111-120 27125675-10 2016 Furthermore, JNK inhibitor SP600125 and Akt (Ser473) inhibitor LY294002 enhanced the inhibition of curcumol on NF-kappaB p65 nuclear translocation. pyrazolanthrone 27-35 nuclear factor kappa B subunit 1 Homo sapiens 111-120 24378536-6 2014 Visfatin also significantly elevated the secretion of IL-6 as well as IL-1beta in a longer incubation period, which was partially suppressed by nuclear factor-kappaB (NF-kappaB) inhibitor, BAY11-7082, and c-Jun-N-terminal kinase (JNK) inhibitor, SP600125. pyrazolanthrone 246-254 nuclear factor kappa B subunit 1 Homo sapiens 144-165 24378536-6 2014 Visfatin also significantly elevated the secretion of IL-6 as well as IL-1beta in a longer incubation period, which was partially suppressed by nuclear factor-kappaB (NF-kappaB) inhibitor, BAY11-7082, and c-Jun-N-terminal kinase (JNK) inhibitor, SP600125. pyrazolanthrone 246-254 nuclear factor kappa B subunit 1 Homo sapiens 167-176 23423712-12 2013 The SP600125 and U0126 neuroprotection appears related to NF-kappaB-regulated transcriptional control of Bcl-2 and XIAP. pyrazolanthrone 4-12 nuclear factor kappa B subunit 1 Homo sapiens 58-67 20398340-9 2010 Phosphorylation analysis of JNK (T183/Y185) and NF-kappaB p65 (S536) showed increased phosphorylation in response to TNFalpha treatment, which was decreased by specific inhibitors of JNK (SP600125) and NF-kappaB (Bay 11-7082, Ro 106-9920). pyrazolanthrone 188-196 nuclear factor kappa B subunit 1 Homo sapiens 48-57 22459175-6 2012 Moreover, NF-kappaB phosphorylation and nuclear translocation was especially noted at the leading edge, which was attenuated by treatment with SP600125 or LY294002. pyrazolanthrone 143-151 nuclear factor kappa B subunit 1 Homo sapiens 10-19 21771752-11 2011 Increased nuclear NF-kappaB activation was blocked by inhibitors of ERK (PD98059) or JNK (SP600125), but not affected by p38 MAPK inhibitor (SB203580). pyrazolanthrone 90-98 nuclear factor kappa B subunit 1 Homo sapiens 18-27 23467542-6 2013 Combination of any two inhibitors of MAPKs (SB203580/U0126 or SB203580/SP600125 or U0126/SP600125) could decrease activation of NF-kappaB. pyrazolanthrone 71-79 nuclear factor kappa B subunit 1 Homo sapiens 128-137 23467542-6 2013 Combination of any two inhibitors of MAPKs (SB203580/U0126 or SB203580/SP600125 or U0126/SP600125) could decrease activation of NF-kappaB. pyrazolanthrone 89-97 nuclear factor kappa B subunit 1 Homo sapiens 128-137 20398340-9 2010 Phosphorylation analysis of JNK (T183/Y185) and NF-kappaB p65 (S536) showed increased phosphorylation in response to TNFalpha treatment, which was decreased by specific inhibitors of JNK (SP600125) and NF-kappaB (Bay 11-7082, Ro 106-9920). pyrazolanthrone 188-196 nuclear factor kappa B subunit 1 Homo sapiens 202-211 18358890-4 2008 LPS-stimulated translocation of nuclear factor kappa B (NF-kappaB) into the nucleus, which was blocked by inhibitors of amino kinase terminal (AKT, LY294002), extracellular signal regulated kinase 1/2 (ERK 1/2, PD98059), p38 (SB203580), and c-jun NH2-terminal kinase (JNK, SP600125) or terrein. pyrazolanthrone 273-281 nuclear factor kappa B subunit 1 Homo sapiens 32-54 20039412-6 2010 RESULTS: TNFalpha-induced VCAM-1 expression, phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK, and translocation of NF-kappaB were attenuated by the inhibitors of MEK-1/2 (U0126), p38 (SB202190), JNK (SP600125), and NF-kappaB (helenalin) or by transfection with their respective shRNA. pyrazolanthrone 203-211 nuclear factor kappa B subunit 1 Homo sapiens 118-127 19428548-7 2009 Treatment with LY294002 (PI3K inhibitor) and SP600125 (JNK inhibitor) suppressed NF-kappaB inhibitor induced MIF mRNA expression and MIF secretion. pyrazolanthrone 45-53 nuclear factor kappa B subunit 1 Homo sapiens 81-90 18336852-5 2008 Furthermore, the involvement of NF-kappaB in TNF-alpha-induced MMP-9 production was consistent with that TNF-alpha-stimulated degradation of IkappaB-alpha and translocation of NF-kappaB into the nucleus which were blocked by helenalin, but not by U0126 and SP600125, revealed by immunofluorescence staining. pyrazolanthrone 257-265 nuclear factor kappa B subunit 1 Homo sapiens 32-41 18358890-4 2008 LPS-stimulated translocation of nuclear factor kappa B (NF-kappaB) into the nucleus, which was blocked by inhibitors of amino kinase terminal (AKT, LY294002), extracellular signal regulated kinase 1/2 (ERK 1/2, PD98059), p38 (SB203580), and c-jun NH2-terminal kinase (JNK, SP600125) or terrein. pyrazolanthrone 273-281 nuclear factor kappa B subunit 1 Homo sapiens 56-65 17586463-3 2007 CTAR2 is known to engage the c-Jun N-terminal kinase (JNK) and NF-kappaB pathways, and we show here that SP600125, a selective JNK inhibitor, suppresses LMP1 potentiation of cisplatin-induced mitochondrial damage and caspase activation in HeLa cells. pyrazolanthrone 105-113 nuclear factor kappa B subunit 1 Homo sapiens 63-72 16979873-4 2007 Here, Western blot and flow cytometric analysis of intracellular kappa staining indicated that upregulation of the expression of kappa was inhibited by using LMP1-targeted DNAzyme and that Bay11-7082 and SP600125, inhibitors of JNK and NF-kappaB, respectively, inhibited LMP1-augmented kappa light chain expression in NPC cells. pyrazolanthrone 204-212 nuclear factor kappa B subunit 1 Homo sapiens 236-245 17303384-7 2007 LPS-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha was blocked by helenalin, U0126, SB202190, or SP600125. pyrazolanthrone 138-146 nuclear factor kappa B subunit 1 Homo sapiens 32-41 17202418-10 2007 It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9. pyrazolanthrone 46-54 nuclear factor kappa B subunit 1 Homo sapiens 187-196 17251521-6 2007 PD-98059, SB-203580, SP-600125, and PDTC-which are inhibitors of ERK1/2, p38, JNK, and nuclear factor-kappaB (NF-kappaB), respectively-attenuated the IL-1alpha-induced COX-2 mRNA expression and activated protein kinase C PGE(2) secretion. pyrazolanthrone 21-30 nuclear factor kappa B subunit 1 Homo sapiens 87-108 17251521-6 2007 PD-98059, SB-203580, SP-600125, and PDTC-which are inhibitors of ERK1/2, p38, JNK, and nuclear factor-kappaB (NF-kappaB), respectively-attenuated the IL-1alpha-induced COX-2 mRNA expression and activated protein kinase C PGE(2) secretion. pyrazolanthrone 21-30 nuclear factor kappa B subunit 1 Homo sapiens 110-119 15971988-6 2005 The JNK inhibitor SP600125 was used as a demonstration compound because in addition to inhibiting nuclear accumulation of phosphorylated c-Jun it reduced nuclear translocation of phosphorylated p38 and NFkappaB p65/RelA in a dose-dependent manner, indicating a lack of SP600125 selectivity. pyrazolanthrone 18-26 nuclear factor kappa B subunit 1 Homo sapiens 202-210 15389584-11 2005 Consistently, IL-1beta stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha which was blocked by helenalin, U0126, or SP600125. pyrazolanthrone 153-161 nuclear factor kappa B subunit 1 Homo sapiens 51-60 14688340-8 2004 Studies conducted to understand the regulation of AP-1 and NF-kappaB activation by JNK MAPK revealed that both DXM and SP600125 inhibited IL-12p40 gene transcription by inhibiting the activation of AP-1 and NF-kappaB transcription factors as revealed by luciferase reporter and gel mobility shift assays. pyrazolanthrone 119-127 nuclear factor kappa B subunit 1 Homo sapiens 59-68 14688340-8 2004 Studies conducted to understand the regulation of AP-1 and NF-kappaB activation by JNK MAPK revealed that both DXM and SP600125 inhibited IL-12p40 gene transcription by inhibiting the activation of AP-1 and NF-kappaB transcription factors as revealed by luciferase reporter and gel mobility shift assays. pyrazolanthrone 119-127 nuclear factor kappa B subunit 1 Homo sapiens 207-216